Current Report Filing (8-k)
December 13 2022 - 04:06PM
Edgar (US Regulatory)
0001680048false00016800482022-12-072022-12-07
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of
1934
Date of report (Date of earliest event reported): December 7, 2022
Mustang Bio, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
|
001-38191
|
|
47-3828760
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
377 Plantation Street
Worcester, Massachusetts 01605
(Address of Principal Executive Offices)
(781)
652-4500
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
|
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.0001 per share
|
|
MBIO
|
|
NASDAQ Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter). ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☒
Item 1.01.Entry into a
Material Definitive Agreement.
As previously disclosed, on March 4, 2022, Mustang Bio, Inc. (the
“Company”) entered into a $75.0 million loan and security agreement
(the “Loan Agreement”) with Runway Growth Finance Corp., as a
lender and as administrative agent and collateral agent for Lenders
(“Runway”).
On December 7, 2022, the Company entered into the First Amendment
(the “First Amendment”) to the Loan Agreement by and between the
Company and Runway. The First Amendment amended certain definitions
and other provisions of the Loan Agreement to replace LIBOR-based
benchmark rates applicable to loans outstanding under the Loan
Agreement with SOFR-based rates, subject to adjustments as
specified in the First Amendment.
The foregoing description of the First Amendment is not intended to
be complete and is qualified in its entirety by reference to the
full text of the First Amendment, a copy of which is filed as
Exhibit 10.1, hereto and is incorporated by reference herein.
Item 9.01.Financial
Statements and Exhibits.
(d) Exhibits.
The following exhibit is furnished herewith:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
|
Mustang Bio, Inc.
|
|
|
(Registrant)
|
|
Date: December 13, 2022
|
|
|
|
By:
|
/s/ Manuel Litchman, M.D.
|
|
|
|
Manuel Litchman, M.D.
|
|
|
|
President and Chief Executive Officer
|
Mustang Bio (NASDAQ:MBIO)
Historical Stock Chart
From Feb 2023 to Mar 2023
Mustang Bio (NASDAQ:MBIO)
Historical Stock Chart
From Mar 2022 to Mar 2023
